News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
this is a very unscrupulous place that allows for such acts to occur.
Huggy, with regards to your post about compensated pumpers,
here’s an interesting SEC Rule that is most likely being violated here:
Section 17(b) of the Securities Act of 1933 ("the Securities Act") mandates that if a person is paid by an issuer to promote a security, the person must disclose the nature, source and amount of such compensation.
The more you post the same press release, the more it does absolutely nothing for the stock.
LOL ROFL PIMPL!
$RGBP CEO Outlines Future Steps in CAR T Program https://finance.yahoo.com/news/regen-biopharma-inc-ceo-outlines-140000342.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$RGBP the next pharma runner here: Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program
RGBP Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program https://finance.yahoo.com/news/regen-biopharma-inc-ceo-outlines-140000342.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
looking good to go up here imo. https://schrts.co/xxVVXEXE
Reposting quotes from the irrelevant press release won't do much to help the pps when one considers that the company is going nowhere fast.
"We have designed a set of sophisticated experiments that test two hypotheses" says Dr. David Koos, Chairman and CEO of the company. "We have selected a CRO with excellent credentials and we expect the results to lay a clear path forward for this program."
Yeah, a good plan alright. As good as all of the other plans they have successfully followed though on to make regen a billion dollar company. Oh, wait……
$RGBP The Company is preparing a series of in vitro studies to test its DuraCAR cells in both immunosuppressive and in tumor-killing experiments. The experiments to explore whether these cells have an immunosuppressive effect include mixing the DuraCAR cells with activated immune cells that are designed to kill target tumor cells and to determine if these cells suppress this killing. In addition, the same experiments will be able to determine if the DuraCAR cells have a direct effect on killing tumors cells.
laughable that they put out a pr telling us about something so routine. This would be like Koos announcing what he's ordering for lunch. And to make it even more of a joke, he doesn't even NAME the CRO.
LOL LLOOOOOOOLLLL
News: Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments
Thu, November 16, 2023 at 9:00 AM EST
In this article: RGBP ,RGBPP
SAN DIEGO, Nov. 16, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) The Company has announced that after interviewing several candidates it has selected a Contract Research Organization (CRO) to perform the next set of experiments to elucidate the effectiveness of the Company's DuraCAR cells.
The Company is preparing a series of in vitro studies to test its DuraCAR cells in both immunosuppressive and in tumor-killing experiments. The experiments to explore whether these cells have an immunosuppressive effect include mixing the DuraCAR cells with activated immune cells that are designed to kill target tumor cells and to determine if these cells suppress this killing. In addition, the same experiments will be able to determine if the DuraCAR cells have a direct effect on killing tumors cells.
"We have designed a set of sophisticated experiments that test two hypotheses" says Dr. David Koos, Chairman and CEO of the company. "We have selected a CRO with excellent credentials and we expect the results to lay a clear path forward for this program."
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION:
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
Email: david.koos@regenbiopharmainc.com or david.koos@regenbiopharma.com
Twitter (now X): https://twitter.com/TheRegenBio
View original content:https://www.prnewswire.com/news-releases/regen-biopharma-inc-selects-contract-research-organization-to-assist-in-duracar-experiments-301989889.html
SOURCE Regen BioPharma Inc.
$RGBP Great Opportunity in the Healthcare Sector! "Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program" https://prn.to/47j50GC $XCPL $PHIL $MCOA $BANT $PVSP $GRLT $INND $BBRW $MMEX $TONR $ICNM $IDVV $MLFB $WISH $NECA $GTCH
Great buying action? Could see $1.50? LOL LOL LOL LOL LOL
Yeah, sure...sure...
Trying to sell manure on here has become a bit more difficult when the con is exposed.
$RGBP nice buying action could see $1.50 by EOD!
Another pile of dung from seekingpumpndumpers. Remember, puttling lipstick on a pile of turd still makes it a turd. And REGEN is turd run by a guy who looks like he is on death's door if you watched the last video of him where he has to ask his paid consultant to remind him what his own company does. What a frickin loser Koos is.
Duracar turned out not to do what they thought it did. It should be renamed DURACRAP.
the farce is strong in that one!
$RGBP EZ Opportunity for Gains LT!
$RGBP - Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program
https://seekingalpha.com/pr/19536297-regen-biopharma-inc-ceo-outlines-future-steps-in-car-t-program?source=tweet @RegenBioPharm $TSLA $AMZN
Keep hope alive, amirite?
Or is it pray for a miracle?
The pump just isn't working like it used to with this scam company run by a scam artist CEO who doesn't even understand his own technology.
If Koos thinks he will get a penny more than the $60K he suck from my pockets, he is MAD wrong. I ain’t selling but he isn’t getting me twice on the same move. He will need to do better. More dilution on the works folks, tight your seatbelts
Time to load up!
RGBP ready to go
LOL! GREAT NEWS THAT REGEN IS GOING TO DO MORE LOW LEVEL IN VITRO LAB TESTING ON SOMETHING THEY COMPLETELY GOT WRONG INITIALLY!
AND QUITE INTERESTING THAT ONE WOULD POST "SMART MONEY IS LOADING HERE" PRIOR TO A PR BEING RELEASED. WHAT ARE THE ODDS OF THAT HAPPENING?
$RGBP has filed patents on shRNA that is designed to inhibit NR2F6 expression in CAR-T Cells and make these CAR-T cells have long-term, durable effectiveness.
👉Currently in pre-clinical development
👉We expect that inhibition of this checkpoint protects CAR-T cells from exhaustion, a common problem of existing CAR-T cell therapies
👉Blocking NR2F6 in CAR-T cells should also make these cells more effective at killing solid tumors.
Great news - The Company is now preparing a series of in vitro experiments to determine if these DuraCAR cells are indeed immunosuppressive, rather than possessing anti-tumor activity as originally envisioned.
"Having had confirmatory studies supporting the increase in NR2F6 gene expression, we now want to see what is happening when these cells are put in a relatively natural environment in the presence of activated immune cells, " says Dr. David Koos, Chairman and CEO of the company. "If these cells do indeed suppress these immune cells, then we will have in hand a potentially extremely valuable approach to suppressing autoimmunity."
Future experiments will then be designed to optimize these cells for protecting against major autoimmune disorders such as type 1 diabetes, colitis and arthritis. $RGBP
$RGBP Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program
https://www.prnewswire.com/news-releases/regen-biopharma-inc-ceo-outlines-future-steps-in-car-t-program-301986597.html
SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html). This program is designed to create chimeric antigen T-cells that silence the gene for NR2F6. As part of the development of this program, it was discovered that NR2F6 mRNA was greatly increased, thus identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html.
The Company is now preparing a series of in vitro experiments to determine if these DuraCAR cells are indeed immunosuppressive, rather than possessing anti-tumor activity as originally envisioned.
"Having had confirmatory studies supporting the increase in NR2F6 gene expression, we now want to see what is happening when these cells are put in a relatively natural environment in the presence of activated immune cells, " says Dr. David Koos, Chairman and CEO of the company. "If these cells do indeed suppress these immune cells, then we will have in hand a potentially extremely valuable approach to suppressing autoimmunity."
Future experiments will then be designed to optimize these cells for protecting against major autoimmune disorders such as type 1 diabetes, colitis and arthritis.
Real smart to upvote your own RGBP post. That gives me the confidence that what you post is the real deal and that I can believe what you are pushing!
LOL
ROFL PIMPL
Smart money loading shares here $RGBP
|
Followers
|
1050
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
118425
|
|
Created
|
09/03/14
|
Type
|
Free
|
| Moderators SmellMyFinger | |||
0.000x Ticker Symbol: RGBP
Barchart
All other Regen BioPharma News
https://www.regenbiopharmainc.com/company-news.html
| Date | Outsanding Shares | Reason for Issue |
|---|---|---|
| 12/31/21 | 4,564,002,832 | |
| 3/28/22 | 4,580,002,832 | Debt and Interest |
| 4/7/22 | 4,736,002,832 | Debt and Interest |
| 5/16/22 | 4,820,002,832 | Debt |
| 7/1/22 | 4,920,002,832 | Debt |
| 7/17/22 | 4,970,002,832 | Debt and Interest |
| 8/1/22 | 5,024,517,324 | Debt |
| 8/4/22 | 5,031,517,324 | EXPENSES |
AI
